Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Mark K. Oki Purchases 10,000 Shares

Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Mark K. Oki purchased 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $28,900. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Achieve Life Sciences Trading Down 4.0 %

Shares of ACHV opened at $2.67 on Thursday. Achieve Life Sciences, Inc. has a 12-month low of $2.51 and a 12-month high of $5.59. The firm has a market capitalization of $92.61 million, a price-to-earnings ratio of -2.36 and a beta of 1.67. The stock’s 50-day moving average price is $3.12 and its 200 day moving average price is $3.97. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). As a group, research analysts predict that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its position in Achieve Life Sciences by 185.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 4,905 shares during the last quarter. Sigma Planning Corp acquired a new position in Achieve Life Sciences during the 4th quarter worth $37,000. ADAR1 Capital Management LLC lifted its holdings in Achieve Life Sciences by 14,375.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 13,082 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in Achieve Life Sciences during the 4th quarter worth $49,000. Finally, Intech Investment Management LLC acquired a new position in Achieve Life Sciences during the 4th quarter worth $58,000. 33.52% of the stock is currently owned by institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.